Last reviewed · How we verify
Comp04
Comp04 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Comp04 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | Comp04 |
|---|---|
| Sponsor | Promius Pharma, LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, Comp04 reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism of action is associated with a reduction in urinary glucose excretion and a decrease in blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comp04 CI brief — competitive landscape report
- Comp04 updates RSS · CI watch RSS
- Promius Pharma, LLC portfolio CI